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Abstract
Background: Improved colorectal cancer (CRC) survival rates have been reported over the last years, with more
than half of these patients surviving more than 5 years after the initial diagnosis. Better understanding these so-
called long-term survivors could be very useful to further improve their prognosis as well as to detect other
problems that may cause a significant deterioration in their health-related quality of life (HRQoL). Cure models
provide novel statistical tools to better estimate the long-term survival rate for cancer and to identify characteristics
that are differentially associated with a short or long-term prognosis. The aim of this study will be to investigate the
long-term prognosis of CRC patients, characterise long-term CRC survivors and their HRQoL, and demonstrate the
utility of statistical cure models to analyse survival and other associated factors in these patients.
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Methods: This is a single-centre, ambispective, observational follow-up study in a cohort of n = 1945 patients with
CRC diagnosed between 2006 and 2013. A HRQoL sub-study will be performed in the survivors of a subset of n =
485 CRC patients for which baseline HRQoL data from the time of their diagnosis is already available. Information
obtained from interviews and the clinical records for each patient in the cohort is already available in a
computerised database from previous studies. This data includes sociodemographic characteristics, family history of
cancer, comorbidities, perceived symptoms, tumour characteristics at diagnosis, type of treatment, and diagnosis
and treatment delay intervals. For the follow-up, information regarding local recurrences, development of
metastases, new tumours, and mortality will be updated using hospital records. The HRQoL for long-term survivors
will be assessed with the EORTC QLQ-C30 and QLQ-CR29 questionnaires.
An analysis of global and specific survival (competitive risk models) will be performed. Relative survival will be
estimated and mixture cure models will be applied. Finally, HRQoL will be analysed through multivariate regression
models.
Discussion: We expect the results from this study to help us to more accurately determine the long-term survival
of CRC, identify the needs and clinical situation of long-term CRC survivors, and could be used to propose new
models of care for the follow-up of CRC patients.
Keywords: Colorectal neoplasms, Long-term survivors, Quality of life, Prognostic factors, Cure
Background
Cancer is one of the most frequent diseases worldwide
and is one of the main causes of hospital admissions.
According to GLOBOCAN data, there were a total of
18.1 million new cancer cases and 9.6 million cancer
deaths in 2018 [1]. In both sexes combined, colorectal
cancer (CRC) is the fourth most commonly diagnosed
cancer and the fifth leading cause of cancer-related
death [1]. Advances in the diagnosis and treatment of
cancer patients have generally increased patient survival
rates. Indeed, according to the American Cancer Society
(ACS), the 5-year survival rate after a cancer diagnosis is
around 65% for all tumours, as well as for CRC in par-
ticular [2]. EUROCARE-5 data indicates that in Europe,
the survival rate 5 years after diagnosis exceeds 50% for
most tumour sites [3]. According to this report, the age-
standardised 5-year survival rate for colon cancer was 57
and 55.8% for rectal tumours [3].
Despite these figures, very few prospective studies have
evaluated the recurrence or mortality rates in survivors
of CRC [4]. Although controversial, a patient with an
oncological process diagnosis is currently considered
‘cured’ when they survive 5 years after diagnosis [5], with
these patients often being referred to as ‘long-term sur-
vivors’. Thus, in CRC, standard follow-up strategies are
usually performed periodically during this period [6].
However, other authors suggest that this ‘cure’ is not
guaranteed for patients who survive the first 5 years after
diagnosis and that follow-up strategies should be modi-
fied according to the risk factors presented by each
patient [4]. Thus, it would be useful to use a rigorous
methodology to determine, in greater detail, the prob-
ability (or percentage) of cured patients, i.e. long-term
CRC survivors, as well as the variables associated with
the prognosis of both these and ‘non-cured’ patients in
order to establish more appropriate follow-up strategies.
Kaplan–Meier curves and the Cox proportional hazard
models are the statistical methods most commonly used
to analyse all-cause mortality in cancer studies, while a
competing-risk analysis is preferred to determine cause-
specific mortality and its associated factors [7]. However,
cure models, which are still not often used, provide an
alternative statistical tool to estimate the cure rates of
cancer patients and analyse the differences between
those individuals who are long and short-term survivors,
as well as to identify covariates associated differently
with short or long-term progosis [8]. Although some
authors have highlighted the usefulness of cure models
as an analysis strategy which could provide especially
useful information for quantifying the improvement in
survival figures in CRC [9], very few publications are
available in this regard. These studies show cure rates of
around 50% and a median survival rate for uncured
patients of about 1 year after diagnosis [9–13]. No such
studies have been undertaken in Spain, and furthermore,
most of this work has been carried out using population
registries and/or do not include clinical information
other than the age at diagnosis, sex, and disease stage,
and therefore, have not used these models to explore the
impact of other covariates on cure rates or survival time.
Data evaluating the long-term health-related quality of
life (HRQoL) of CRC survivors are also scarce, although
work studying the first 5 years after their diagnosis is
more common [14]. Recent work suggests that these
patients present a HRQoL similar to that of the general
population, although some factors such as intestinal
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dysfunction can contribute to their deterioration, even
15 years after their initial diagnosis [14]. Furthermore,
these results should be contrasted with those obtained
in other cohorts and in different locations. Therefore,
this study was planned with the aim of determining the
long-term prognosis in CRC patients, to characterise
long-term survivors and their HRQoL, and demonstrate
the utility of statistical cure models in the study of CRC
survival. Results from this study may be useful to deter-
mine the cure rate (proportion of long-term survivors)
in CRC, the survival rates of ‘uncured’ patients and asso-
ciated factors, and to develop a predictive model to iden-
tify long-term survivors from among CRC patients. In
addition, it will also allow us to describe HRQoL and the
prevalence of symptoms in these patients.
Methods/design
Objectives
The goals of this project are
i. To determine the long-term survival rates of CRC
patients and the variables associated with the
prognosis.
ii. To ascertain the cure rate (proportion of long-term
survivors) for CRC and the survival rate for un-
cured patients as well as the factors associated with
these by using mixture cure models.
iii. To develop a predictive model to identify long-term
survivors from among patients diagnosed with
CRC.
iv. To determine the HRQoL and prevalence of
symptoms in long-term survivors of CRC.
Design
This is a single-centre follow-up observational study of
cases of CRC diagnosed in the Complexo Hospitalario
Univesitario A Coruña (A Coruña, northwest Spain)
from 2006 to 2013 (n = 1945), previously included in
some of our other research projects [15–17]. A quality
of life sub-study will be carried out in the patients in-
cluded in the framework of one of these other projects
[17] who have not died at the time of this present study
(n = 485), in order to assess their current HRQoL and
compare it with their baseline HRQoL scores when the
CRC was initially diagnosed.
Inclusion and exclusion criteria
Every case of CRC diagnosed during the 2006–2013
period was included. We excluded prevalent or recurrent
cases, multiple cancer cases, cases detected by CRC
screening, and cases diagnosed in another hospital but
referred to our centre for treatment.
Sample size
A cohort of n = 1945 incident CRC cases is available
from previous research projects. Assuming exposure
of 50% and a censored data percentage of 58% [3,
18], this sample size will make it possible to use a
Cox regression model to detect significant changes
with a hazard ratio (HR) of 1.22 or more (security =
95%; statistical power = 80%). Based on the available
survival figures of the n = 485 patients included in a
previous project for whom baseline HRQoL data are
available [17], we estimate that around n = 281 pa-
tients will still be alive at the time of this proposed
study. Assuming loses of around 30%, to estimate
HRQoL with 95% confidence and at ±7% precision,
we estimate that some n = 200 patients will need to
be included in this HRQoL sub-project.
Data collection
Cases were identified via the Pathological Anatomy
Service at our hospital and the specialists who followed-
up the patients were also responsible for their recruit-
ment. After signing their informed consent to participa-
tion, we interviewed the patients and reviewed their
primary and specialised care clinical history. We already
have a computerised database in which we have col-
lected the information from the framework of our other
research projects [15–17]. In the case of the HRQoL
sub-study, non-deceased patients will be informed of the
objectives of this present study during one of their
follow-up visits to the hospital. The HRQoL question-
naires will be completed after they grant their informed
consent to participation in this new study.
Measurements
Information about each patient was obtained in our pre-
vious studies and is detailed in our other publications
[15–17]. This data includes
a. Sociodemographic data: age at the time of the CRC
diagnosis, sex, civil status, and education level.
b. Patient interview data: perceptions and attitudes to
the first symptoms of CRC.
c. Personal or family history of cancer or other
neoplasms.
d. Comorbidities (Charlson comorbidity index).
e. Disease presentation variables: first symptoms/signs,
access to primary and specialised care, first
consultation service, examinations and
complementary tests prior to the diagnosis,
laboratory tests at the time of the diagnosis.
f. Diagnosis and treatment delay.
g. Tumour characteristics at the time of diagnosis:
tumour size, site, histological grade, macroscopic
appearance, permeation, stage (TNM and Dukes),
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location of metastases, and infiltration of adjacent
organs.
h. Surgical treatment: curative or palliative surgery,
type of surgery, access route (laparoscopic vs. open
CRC surgery), type of anastomosis, resection of
other viscera, resectability, surgical border
infiltration, surgical morbidity, and reinterventions
and their causes.
i. Chemotherapy or radiation treatments.
j. Complementary tests during follow-up: hospital
consultations and physical examinations, laboratory
tests, chest X-rays, abdominal ultrasound, colonos-
copies, computed tomography, barium enema, and
positron emission tomography.
The follow-up data that will be updated in this project
include mortality (global and specific), local recurrences,
distant metastases, and new-onset neoplasms, together
with the date of each of these events. Non-deceased
patients will be censored at the end of follow-up or on
the latest date for which evidence is available for that
patient.
In addition to the data described above, we will also
record information about the HRQoL for the patients in
the quality of life sub-study (n = 485 CRC patients diag-
nosed from 2010 to 2013) 3 to 6 months from the time
of the CRC diagnosis. HRQoL measurements are also
available 1 year after diagnosis for n = 214 of these
patients, and 2 years after the diagnosis in n = 195
patients. For the patients in this sub-cohort who are still
alive when this project is carried out, information will be
collected about their current HRQoL using the general
module of version 3.0 of the European Organization
for Research and Treatment of Cancer (EORTC)
QLQ-C30 questionnaire [19] which is applicable to all
cancer patients. We will also apply the EORTC QLQ-
CR29 module which is specific to colon and rectal
cancer patients [20].
Statistical analysis
Overall and cancer-specific survival analysis
Overall survival will be analysed using Kaplan–Meier
curves, bivariate log-rank tests, and multivariate Cox
proportional-hazards models. For cancer-specific and
disease-free survival, a competing risk analysis will be
performed. The cumulative incidence of CRC-related
death in the follow-up will be estimated considering
death from other causes as a competing risk, using the
method proposed by Kalbfleisch and Prentice [21].
Disease-specific mortality will be compared according to
different characteristics, using Gray’s test [22]. Finally, a
multivariate analysis will be performed using the model
proposed by Fine and Gray [23].
Relative survival
Relative survival will be estimated as the ratio of
observed survival of CRC patients and the survival that
would have been expected if the patients had had the
same mortality rate as the general population. The
expected survival will be estimated from the population
mortality rates estimated for the health area by age
group, sex, and study year, using the Ederer II method
[24]. Following other publications, the ‘statistical cure’
point will be defined as the point at which the relative
survival curve plateaus, e.g., when the patients remaining
alive experience the same mortality rate as the age and
sex-matched population without cancer [9–13]. Thus,
the value at which the plateau is achieved will provide
an estimation of the curation rate.
Cure models
The cure rate and ‘latency’ (time to death or recurrence)
will be estimated using parametric and semi-parametric
mixture cure models [8]. For parametric models, logistic
regression will be used to analyse the cure fraction
and the Weibull distribution will be used to model
the survival probability of uncured patients. For semi-
parametric analysis, long-term survival will be mod-
elled using a Cox proportional-hazards model. The
following results will be obtained from the estimates
of the models, (a) the cure rate; (b) relative survival
curves for all the patients and for uncured patients;
(c) median survival rates in uncured patients; and (d)
the timepoint at which 90% of the uncured patients
have died. Estimates will be obtained for each sex
and CRC location (colon vs. rectum), according to
age (15–49, 50–59, 60–69, 70–79, and 80–99), and
year of diagnosis. Using these models, the effect of
different covariates on the cure rate and survival of
the uncured patients will be determined independ-
ently. The parameters of the model will be estimated
using the maximum likelihood method.
Quality of life
The mean HRQoL questionnaire scores and the preva-
lence of associated symptoms will also be determined,
together with their 95% confidence intervals. HRQoL
will be compared with the baseline data using statistical
analysis tests for paired data in order to determine the
factors associated with a better HRQoL. We will test the
normality of the quantitative variables using the Kolmo-
gorov–Smirnov test and will apply Student t-tests or
Mann–Whitney U tests as appropriate to compare
numerical parameters between two groups. An analysis
of variance or the Kruskall–Wallis test will be used to
compare more than two groups. The association
between qualitative variables will be contrasted using the
chi-square statistic and associations between quantitative
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variables will be studied with Pearson correlation coeffi-
cients and Spearman’s rho. Linear regression and mul-
tiple logistic models will be used to control for the effect
of several variables on HRQoL, perceived quality of care,
and patient function. All the statistical analyses will be
carried out with SPSS (version 21.0; IBM Corp.,
Armonk, NY) and R software for Windows.
Discussion
CRC is a major public health problem worldwide and is
one of the most common tumour types in terms of its
incidence and associated mortality rates [1]. Advances in
the diagnosis and treatment of CRC has caused its mor-
tality rates to decrease in recent years, thus increasing
the number of long-term CRC survivors [3]. These sur-
vivors experience the normal issues related to aging,
along with the physical and emotional effects of a cancer
diagnosis and of its treatments [25]. Therefore, one goal
remains further improvement of the probability of ‘cur-
ing’ this disease while also improving the life expectancy
for these cured patients.
Thus, large epidemiological studies are important to
check the effects of diagnosis and treatment improve-
ments in terms of patient survival, to identify prognostic
factors, and to detect subgroups who could need more
frequent follow-up surveillance. Therefore, the primary
endpoint of this proposed study will be to provide an ac-
curate, updated estimation of long-term survival in CRC
patients, as well as to identify variables that may be asso-
ciated with the probability of a cure and with survival
time in uncured patients.
Traditional statistical methods (such as Kaplan–Meier
curves or the Cox proportional hazards model) com-
monly used to estimate survival in CRC patients, impli-
citly assume that all patients with the same global
diagnosis of CRC are at risk of developing the event of
interest (e.g., death from the tumour) if they are
followed for a sufficiently long period of time. This
hypothesis is reasonable when overall mortality is ana-
lysed, but falls short when analysing specific-cause mor-
tality or disease-free survival because some patients will
never die from the CRC cancer or suffer a recurrence of
the tumour. Therefore, alternative survival models taking
this into account should be considered.
Statistical cure models could be a useful alternative in
this context, even though they are not often currently
used in clinical research [26]. Cure models assume that
a fraction of the patients will be cured by the treatment
and will never be at risk for suffering an event related to
the specific disease again (e.g., CRC death, recurrence,
or metastases). Therefore, these models might provide a
better estimation of the ‘cure fraction’ while also model-
ling the average time to the occurrence of a new event
among uncured patients as well as associated prognosis
factors. These models therefore allow the clinical deter-
minants of the cure and the variables associated with
survival to be analysed [27].
To the best of our knowledge, this is the first study in
Spain employing cure models to analyse the long-term
prognosis of CRC patients. Furthermore, no other pub-
lished studies have evaluated the impact of clinical vari-
ables other than age, sex, disease stage, or location on
long-term CRC survival by using a similar methodology.
The research published to date are mainly cancer-
registry population studies that do not include clinically
important variables such as those registered in hospital-
based cohort studies like this one. Other strengths of
this project are its relatively large sample size and the
long-term follow-up periods considered.
Health care for long-term survivors must include strat-
egies not only for the early diagnosis of recurrences and
new neoplasms, but also to detect the long-term medical
and psychological effects of cancer diagnosis and treat-
ments [25]. Thus, characterisation of long-term survi-
vors and analysis of their outcomes will help researchers
to assess the adequacy of the medical care provided to
them and to optimise the health resources invested in
these patients. The secondary aims of this project will be
to provide information on the symptoms and HRQoL of
long-term CRC patients. These results will allow us to
confirm whether, as other authors have indicated,
HRQoL returns to normal 1 year after diagnosis [28].
This data could be important to CRC patients, for
example, in planning scheduled follow-up visits to
screen not only for medical issues, but also for the late
effects of treatments on patient HRQoL and symptoms.
Finally, this research is not without limitations. Firstly,
it is a single-centre study which includes a sample from
only one hospital in Spain. Secondly, some of the mea-
surements were obtained from clinical records, and so
the possibility of information bias could not be dis-
carded. This could limit the generalisability of the results
and so, future studies including other populations are
warranted. Nonetheless, this study reflects the outcomes
of real-life practice in a specialised hospital. Moreover,
because it is a single-centre study, the procedures, met-
rics, and variables collected were homogeneous. In sum-
mary, this study had a large sample size and long follow-
up time and its results are expected to help identify the
needs and clinical situation of long-term survivors of
CRC and will be useful for proposing new models of
care for the follow-up of these patients.
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